journal article·2018-11-05Open access

Anti-proliferate and apoptosis triggering potential of methotrexate-transferrin conjugate encapsulated PLGA nanoparticles with enhanced cellular uptake by high-affinity folate receptors

Ankush Parmar, Atul Jain, Shivani Uppal, S. K. Mehta, Khuswinder Kaur, Bhupinder Singh, Rajat Sandhir, Shweta Sharma

Abstract

-coated FA-PNPs in lowering the drug diffusion rate by 88.4% (after 30 min) and three-fold enhanced retention time of drug in systemic circulation, thereby felicitating an effective prognostic treatment. This study clearly demonstrated reduced systemic toxicity, enhanced biocompatibility and anti-tumour efficacy of formulated NPs.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Drug Transport and Resistance Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Forensic Science & Criminology, Panjab University, Chandigarh, India;

UGC-Centre of Excellence in Applications of Nanomaterials, Nanoparticles & Nanocomposites (Biomedical Sciences), Panjab University, Chandigarh, India;

Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University, Chandigarh, India;

Department of Biochemistry, Panjab University, Chandigarh, India

References (36)

Show source-provided references
1. 10.1080/09205063.2015.113315510.1080/09205063.2015.1133155 ↗
2. 10.1016/j.jconrel.2007.05.02210.1016/j.jconrel.2007.05.022 ↗
3. 10.1007/s11481-006-9025-310.1007/s11481-006-9025-3 ↗
4. 10.1016/j.actbio.2015.06.02710.1016/j.actbio.2015.06.027 ↗
5. 10.1016/j.biomaterials.2007.06.01110.1016/j.biomaterials.2007.06.011 ↗
6. 10.1016/j.ijpharm.2005.11.04010.1016/j.ijpharm.2005.11.040 ↗
7. 10.1016/S0169-409X(98)00091-X10.1016/S0169-409X(98)00091-X ↗
8. 10.1038/bjc.1998.74710.1038/bjc.1998.747 ↗
9. 10.1016/j.trac.2015.06.01410.1016/j.trac.2015.06.014 ↗
10. 10.1016/j.jconrel.2012.01.04310.1016/j.jconrel.2012.01.043 ↗
11. 10.1016/j.jconrel.2011.08.01710.1016/j.jconrel.2011.08.017 ↗
12. 10.1016/j.biomaterials.2013.07.10210.1016/j.biomaterials.2013.07.102 ↗
13. 10.1002/jbm.a.3528610.1002/jbm.a.35286 ↗
14. 10.1016/j.jconrel.2009.09.02010.1016/j.jconrel.2009.09.020 ↗
15. 10.1016/j.bmcl.2016.12.03610.1016/j.bmcl.2016.12.036 ↗
16. 10.1016/j.bbr.2006.06.00110.1016/j.bbr.2006.06.001 ↗
17. 10.1016/S0169-409X(00)00139-310.1016/S0169-409X(00)00139-3 ↗
18. 10.1016/j.apsb.2013.08.00110.1016/j.apsb.2013.08.001 ↗
19. Lee RJ · J Biol Chem · 1994 · 269 · 319810.1016/S0021-9258(17)41848-5 ↗
20. 10.1039/C4OB00150H10.1039/C4OB00150H ↗
21. 10.1016/j.ijpharm.2016.11.01210.1016/j.ijpharm.2016.11.012 ↗
22. 10.1016/j.colsurfa.2005.10.06410.1016/j.colsurfa.2005.10.064 ↗
23. 10.1016/j.ejpb.2008.03.00910.1016/j.ejpb.2008.03.009 ↗
24. 10.1016/j.ejps.2012.09.01210.1016/j.ejps.2012.09.012 ↗
25. 10.1016/j.colsurfb.2016.05.05110.1016/j.colsurfb.2016.05.051 ↗
26. 10.1021/mp700086j10.1021/mp700086j ↗
27. Ballangrud ÅM · Clin Cancer Res · 1999 · 5 · 3171s
28. 10.1016/j.ijrobp.2005.09.00410.1016/j.ijrobp.2005.09.004 ↗
29. 10.1039/C5NR00733J10.1039/C5NR00733J ↗
30. 10.1016/j.biomaterials.2009.01.00510.1016/j.biomaterials.2009.01.005 ↗
31. 10.1016/j.ejphar.2011.09.02310.1016/j.ejphar.2011.09.023 ↗
32. 10.1039/C6RA17290C10.1039/C6RA17290C ↗
33. 10.1039/b801262h10.1039/b801262h ↗
34. 10.1016/j.biomaterials.2012.09.04710.1016/j.biomaterials.2012.09.047 ↗
35. 10.1016/j.jconrel.2008.04.01310.1016/j.jconrel.2008.04.013 ↗
36. 10.1016/j.biomaterials.2007.04.00410.1016/j.biomaterials.2007.04.004 ↗